Vimarsana
Biggest News Aggregation in the World

Charles Randquist News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Charles Randquist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Charles Randquist Today - Breaking & Trending Today

Establishment Labs Begins a New Era in Breast Aesthetics with Launch of Mia Femtech in Japan - Vimarsana News

Establishment Labs Begins a New Era in Breast Aesthetics with Launch of Mia Femtech in Japan

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the launch of Mia Femtech™ (“Mia®”) in Japan, marking the beginning of a new era in...

Establishment Labs Begins a New Era in Breast Aesthetics with Launch of Mia Femtech in Japan - Vimarsana News

Establishment Labs Begins a New Era in Breast Aesthetics with Launch of Mia Femtech in Japan

Establishment Labs Holdings Inc. , a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced... | April 10, 2023

Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica - Vimarsana News

Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica

Published: Dec 10, 2020 SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia ® system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond ® breast implant, and has completed the procedure in the first 21 patients in the study. “Motiva Mia is...